Congenica named in UK life sciences – Catalysing investment and growth report
Congenica is pleased to be named in the BioIndustry Association (BIA) report, ‘UK life sciences – Catalysing investment and growth’ published 17th June 2019.
The report sets out how the UK life sciences sector is driving investment and growth and makes the case for increased cost-effective public investment in the sector. The report aims to inform the Government, UK Research and Innovation (UKRI), and other policymakers as they prepare for the forthcoming Spending Review and develop an R&D roadmap to reach the target of raising R&D investment to 2.4% of GDP by 2027.
In this report, Congenica is highlighted as a case study on innovative life sciences SMEs in the UK.
Speaking to the BIA, Congenica Chief Executive Officer, David Atkins commented: “Congenica’s future looks extremely positive as we continue to be strong exporters of world class, home‑grown UK innovation to bring significant benefit to patients and families across the globe. Without question, we would not be where we are today without the financial support received from both public and private sources.”
Click here to read and download the full report.
About the BIA
Established over 25 years ago at the infancy of biotechnology, the BIA is the trade association for innovative life sciences in the UK. Their goal is to secure the UK’s position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people’s lives.